Eptinezumab is a preventive medication for migraine treatment. It belongs to a class of drugs called CGRP inhibitors, which work by blocking a protein involved in causing migraine headaches. This medication is given as an intravenous infusion and is specifically designed to help people who suffer from both migraine headaches and medication overuse headache (a condition that occurs from using too many pain medications). The medication aims to reduce the frequency and severity of migraine attacks while helping patients who are using too many acute headache medications.

Brief Education Intervention (BI) is not a medication but rather a therapeutic approach that involves teaching patients about their condition and providing strategies to manage their headaches. This intervention includes education about migraine triggers, lifestyle modifications, and proper use of medications to prevent medication overuse headache.

Chronic Migraine – A neurological condition characterized by headaches occurring on 15 or more days per month for more than three months, with at least eight of those days featuring migraine symptoms. The pain typically affects one side of the head and may be accompanied by nausea, sensitivity to light and sound, and visual disturbances.

Migraine – A neurological disorder characterized by recurring headaches that typically cause moderate to severe throbbing pain, usually on one side of the head. Episodes can last from several hours to days and are often accompanied by nausea, vomiting, and sensitivity to light and sound. Some people experience warning symptoms called aura before the headache begins.

Medication Overuse Headache – A secondary headache disorder that develops as a result of regular, long-term use of headache medication. It occurs when pain relievers are taken for headaches 15 or more days per month. The condition creates a cycle where frequent use of pain medication leads to more frequent headaches, prompting increased medication use.